🫀 Semaglutide for Obesity—Cochrane Review: Sustained, Clinically Relevant Weight Loss, CV Signal Confirmed

🔥 Main in 3 points

• Semaglutide ensures robust weight loss vs placebo: mean difference (MD) –10.73% at 6–17 months (high-certainty).
• Reduces risk for MACE (RR 0.63, 95% CI 0.44–0.90) and mortality (RR 0.69, 95% CI 0.48–0.98), though absolute benefits are modest.
• Increases mild/moderate GI adverse events and withdrawals (long-term: RR for withdrawal 2.03) but not serious AEs.

🧪 Context

Cochrane meta-analysis of 18 RCTs (n = 27,949; mean age 41–69.5; avg BMI 32–40.3) assessed semaglutide vs placebo for adults with obesity (≥6 months). Additional comparators: liraglutide, tirzepatide.

📍 Practical significance

Semaglutide remains the most evidence-backed GLP-1RA for sustained weight reduction and reduction in CV events/mortality in obesity, independent of baseline risk. GI AEs and treatment discontinuation remain principal limiting factors—counsel on titration and expectations. Await further independent/long-term safety data.

🔗 Source

PubMed | DOI

🧪 SELECT Trial: Semaglutide CV Protection Is Independent of Baseline Adiposity

🩸 What was studied

Prespecified subanalysis of SELECT RCT (n = 17,604; age ≥45; BMI ≥27; CV disease, no diabetes): semaglutide 2.4 mg weekly vs placebo; outcome—major adverse CV events (MACE) by baseline and changes in bodyweight/waist circumference.

📈 Key results

• Semaglutide reduced MACE across all baseline adiposity (HR ~0.96 per –5kg/–5cm WC).
• Weight loss per se did not explain MACE benefit, but WC reduction did: 33% of MACE reduction mediated by WC change.
• In placebo, weight loss paradoxically associated with ↑MACE risk.

📍 What this changes in practice

Semaglutide's cardioprotective effect in overweight/obese patients is largely independent of weight loss, with a modest additional benefit from waist reduction. Reinforce semaglutide's role in high CV risk obesity—do not restrict to those with severe adiposity.

🔗 Source

PubMed | DOI

🧾 Semaglutide in Type 1 Diabetes: Insulin Pump Dosing Requires Early, Ongoing Adjustment

✅ Do

• Expect rapid reduction in total/bolus insulin needs by day 7 of semaglutide initiation; reduce carbohydrate inputs accordingly.
• Monitor and adjust basal by day 32, with ongoing titration of pump parameters.

⚠️ With caution

• Even with CGM/AID tech, individualized pump setting changes are essential to avoid hypoglycemia.
• Maintain close follow-up during early dose titration phase.

🔗 Source

PubMed | DOI

⚠️ Perioperative Aspiration Risk: Residue-Free Diet and GLP-1RA Withdrawal May NOT Prevent Complications

🧪 Context

Case report: 61F, elective angiography on weekly semaglutide for weight loss (discontinued 6 days before procedure), otherwise abided by 24h residue-free diet/12h fasting.

📊 Numbers

Despite protocol adherence, large-volume aspiration occurred during induction. Prior semaglutide use undisclosed.

📍 Actions

• Intensify perioperative screening: proactively ask, document GLP-1RA use.
• Consider interruption intervals >7 days for elective procedures.
• Routinely use bedside gastric ultrasound before anesthesia on known/suspected GLP-1RA users.

🔗 Source

PubMed | DOI

🩸 Real-World Data: Semaglutide vs Standard of Care for Glycemic Control

🔥 Main in 3 points

• Propensity-matched RWE cohort (n = 1,144 pairs): semaglutide initiators were 30% more likely to achieve HbA1c <7% vs SoC ( risk ratio 1.30 [1.16–1.45]).
• A1c reduction: –1.3% with semaglutide vs –1.1% with SoC.
• Results closely mirrored interim SEPRA phase IV RCT.

🧪 Context

Adults with T2D on metformin, starting injectable semaglutide or SoC (DPP4, SGLT2, SU, other GLP-1RA), using large national claims data.

📍 Practical significance

Supports semaglutide’s real-world advantage for glycemic control after metformin. Fit-for-purpose RWE studies can complement RCTs in rapid comparative effectiveness evaluations.

🔗 Source

PubMed | DOI

🛡️ GLP-1RA Reduces Aortic Dilatation Progression in T2DM—Vasoprotective Beyond Glycemic Control

🧪 What was studied

Prospective study (n = 127 T2DM with subclinical ascending aortic dilatation): GLP-1RA (liraglutide, semaglutide, dulaglutide) vs standard care over 24 months.

📈 Key results

• Aorta dilatation progression significantly less with GLP-1RA: +0.36mm vs +1.05mm (p<0.001).
• Favorable biomarker shifts (↓MMP-9, CRP; ↑TIMP-1, OPG).
• GLP-1RA use was an independent predictor of reduced aortic dilatation.

📍 What this changes in practice

GLP-1RA therapy may confer vascular protection in T2DM with subclinical aortic dilatation. Consider for patients at risk of aortic disease as additional benefit.

🔗 Source

PubMed | DOI

📈 GLP-1RA in Craniopharyngioma-Associated Hypothalamic Obesity: Semaglutide Is Effective but Requires Endocrine Vigilance

🧪 What was studied

Multicentre RWE study (n = 116 adults post-craniopharyngioma, hypothalamic obesity; mean BMI 40), >44 months follow-up.

📈 Key results

• Mean WL: –4.6% (high interindividual variability); 51% had ≥5% WL, 28% had ≥10% WL.
• Semaglutide yielded greatest WL (–6.8%; –8.5% for nondiabetics).
• 12% adrenal/10% vasopressin deficiency decompensations; 13% stopped due to GI intolerance.

📍 What this changes in practice

GLP-1RAs (esp. semaglutide) offer modest benefits in hypothalamic obesity post-CP, but require diligent endocrine surveillance for adrenal/vasopressin balance and GI AEs—integrate close monitoring into practice.

🔗 Source

PubMed | DOI